DICE Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical firm focused on developing novel oral therapeutics for chronic diseases, has announced its participation in key investor conferences. Management will present at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, and the Stifel 2022 Healthcare Conference on November 16, 2022. Additionally, a fireside chat is scheduled for the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022. Presentations will be available for 90 days post-event on the company's website.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the following investor conferences:

• Guggenheim 4^th Annual Immunology and Neurology Day
  Fireside chat: Tuesday, November 15, 2022 at 11:20 a.m. EST

• Stifel 2022 Healthcare Conference
  Presentation: Wednesday, November 16, 2022 at 8:00 a.m. EST

• Evercore ISI 5^th Annual HealthCONx Conference
  Fireside chat: Wednesday, November 30, 2022 at 3:05 p.m. EST

Live and archived webcasts of the presentations will be accessible under “News & Events” in the Investors section of the company's website for 90 days after the applicable event.

About DICE Therapeutics, Inc.
DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Contacts:

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
investors@dicetx.com

FAQ

What investor conferences is DICE Therapeutics attending in November 2022?

DICE Therapeutics will attend the Guggenheim 4th Annual Immunology and Neurology Day on November 15, Stifel 2022 Healthcare Conference on November 16, and Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022.

When is DICE Therapeutics presenting at the Guggenheim conference?

DICE Therapeutics will present at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 11:20 a.m. EST.

Where can I watch DICE Therapeutics' conference presentations?

The presentations by DICE Therapeutics will be accessible live and archived under the 'News & Events' section in the Investors area of their website for 90 days following each event.

What is the focus of DICE Therapeutics' drug development?

DICE Therapeutics focuses on developing oral therapeutics targeting chronic diseases in immunology, specifically aiming to create oral antagonists for pro-inflammatory signaling molecules.

What are the key targets for DICE Therapeutics' drug candidates?

DICE Therapeutics' lead candidates target the pro-inflammatory molecule IL-17, and they are also developing therapies for inflammatory bowel disease and idiopathic pulmonary fibrosis.